Dash 70mg Tablet (Dasatinib)
Prescription RequiredManufactured By
Bdr pharma
Pack Of
60
Salt Composition
Dasatinib
Storage
Store below 30°C
Fast Delivery
Easy Returns
Secure Payments
Up to 60% Discounts
ALL SUBSTITUTES
Sprycel 70mg Tablet
Dasanat 50mg Tablet
Dasakast 50mg Tablet
Dasacine 50mg Tablet
Dasazest 70mg Tablet
Dasamac 70mg Tablet
Spnib 70mg Tablet
Dasashil 70mg Tablet
Beedan 70mg Tablet
Nextki 50mg Tablet
Dyronib 50mg Tablet
Sprycel 50mg Tablet
Spnib 50mg Tablet
Overview
Dash 70mg Tablet contains dasatinib 70 mg, an oral tyrosine kinase inhibitor active against BCR::ABL1 and SRC-family kinases. It is used for Philadelphia-chromosome-positive CML and Ph-positive ALL. Dasatinib 70mg tablet is more potent in vitro than imatinib against BCR::ABL1 and retains activity against many imatinib-resistant mutations, but not T315I. The 70 mg tablet is a strength rather than the usual adult chronic-phase CML dose; modern chronic-phase regimens commonly use 100 mg once daily.
Quick Product Facts
| Field | Publication wording |
|---|---|
| Brand | Dash 70mg Tablet |
| Molecule / Combination | Dasatinib |
| Strength / Composition | 70 mg |
| Dosage form | Tablet |
| Manufacturer / Marketer | [Verify exact physical pack] |
| Pack / Presentation | 60 tablets on current Indian listing |
| Storage | Store at room temperature; verify exact pack. |
| Prescription | Required |
| Publication status | Medical-review sign-off required |
Uses and Indications
Dasatinib 70mg tablet is used for newly diagnosed chronic-phase Ph-positive CML and for chronic, accelerated or blast-phase CML with resistance/intolerance to prior therapy. It is also used in Ph-positive ALL in selected settings, often with chemotherapy or steroid-based regimens. Treatment selection should incorporate BCR::ABL1 mutation testing after resistance, cardiovascular/pulmonary history and alternatives such as other TKIs.
How Dash 70mg Tablet Works
Dasatinib 70mg tablet binds multiple conformations of the BCR::ABL1 kinase and also inhibits SRC-family kinases, reducing proliferation of Philadelphia-chromosome-positive leukaemic cells.
Clinical Evidence for Dash 70mg Tablet
DASISION: Dasatinib 7mg achieved faster/deeper molecular responses than imatinib in newly diagnosed chronic-phase CML.
Resistant CML/Ph+ ALL studies: Dasatinib 70mg tablet demonstrated activity after imatinib resistance/intolerance across advanced disease phases.
Side Effects of Dash 70mg Tablet
Common or Clinically Frequent Side Effects
- ● Low blood counts
- ● Fluid retention
- ● Headache
- ● Diarrhoea
- ● Rash
- ● Musculoskeletal pain
Serious Side Effects
- ● Pleural effusion
- ● Pulmonary arterial hypertension
- ● Severe myelosuppression
- ● Bleeding
- ● QT prolongation
- ● Severe fluid retention
Critical Safety Warning
PLEURAL EFFUSION/PAH WARNING: dasatinib 70mg tablet can cause recurrent pleural effusions and pulmonary arterial hypertension, sometimes after years of therapy. New breathlessness, dry cough, chest discomfort or reduced exercise tolerance requires assessment.
Dash 70mg Tablet Dosage and How To Take It
Clinical context | Typical labelled / protocol guidance |
Chronic-phase CML common adult dose | 100 mg once daily. |
Advanced-phase CML/Ph+ ALL common dose | 140 mg once daily under the reference label |
70 mg tablet | May be used to construct specific doses; do not assume one tablet equals the prescribed dose |
Acid-reducing therapy | PPIs and H2 blockers reduce absorption and should generally be avoided; antacids require separation. |
Important: Dose and regimen must be prescribed by the treating specialist. Tablet/vial strength is not necessarily the patient dose. Do not start, stop, split, combine or substitute treatment based on website information.
Dash 70mg Tablet Missed Dose
Take a missed dose according to the prescribed schedule; do not double. If uncertain, contact the treatment team.
Safety Advice for Dash 70mg Tablet
| Category | Status | Guidance |
|---|---|---|
| Lung/pleura | Monitor | Assess dyspnoea and effusion symptoms. |
| Heart/QT | Caution | Review QT-prolonging risks/electrolytes. |
| Pregnancy | Avoid | Can cause fetal harm. |
| Bleeding | Monitor | Platelet dysfunction and cytopenias increase risk. |
| Driving | Caution | Dizziness/fatigue may occur |
Monitoring During Dash 70mg Tablet Treatment
● CBC
● BCR:ABL1 PCR response
● Pleural effusion symptoms
● Cardiac/pulmonary evaluation when indicated
● Electrolytes/QT risk
● Mutation testing if failure occurs
Dash 70mg Tablet Fact Box
| Parameter | Verified / publication wording |
|---|---|
| Brand | Dash 70mg Tablet |
| Generic / Combination | Dasatinib |
| Strength | 70 mg |
| Form | Tablet |
| Manufacturer / Marketer | [Verify exact physical pack] |
| Pack | 60 tablets on current Indian listing |
| Storage | Store at room temperature; verify exact pack. |
| Major safety theme | PLEURAL EFFUSION/PAH WARNING |
| Prescription | Yes |
Dash 70mg Tablet Drug Interactions
| Drug / Class | Risk | What To Do |
|---|---|---|
| PPIs/H2 blockers | Reduce dasatinib 70mg absorption | Avoid where possible. |
| Antacids | Reduce absorption | Separate by at least the label-specified interval. |
| Strong CYP3A4 inhibitors | Increase exposure | Avoid/adjust. |
| Strong CYP3A4 inducers | Reduce exposure | Avoid. |
FAQs About Dash 70mg Tablet
Is 70 mg the usual chronic-phase dose?
No. A common adult chronic-phase dose is 100 mg once daily.
Why can dasatinib 70mg cause shortness of breath?
Pleural effusion and, rarely, pulmonary arterial hypertension can occur.
Can I take a PPI?
PPIs reduce dasatinib tablet absorption and are generally avoided.
Which mutation is resistant to dasatinib 70mg?
BCR::ABL1 T315I is resistant and requires another strategy.
How is response monitored after dasatinib treatment?
Regular BCR::ABL1 PCR testing measures molecular response.
Can dasatinib treatment cause bleeding?
Yes, through thrombocytopenia and platelet-function effects.
How long is dasatinib 70mg treatment?
Often long-term, with treatment-free-remission strategies considered only under strict specialist criteria.
Who markets Dash 70mg Tablet?
It is possible to verify the availability of dash tablet by contacting any licensed pharmacy or reputable online pharmacy. Current stock and prescription fulfillment can be confirmed by visiting their website.
References
1. Current dasatinib 70mg tablet prescribing information (Sprycel/reference). https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021986s7s8lbl.pdf
2. Cortes JE, et al. DASISION. Journal of Clinical Oncology/Blood updates. https://ascopubs.org/doi/10.1200/jco.2011.29.15_suppl.6510
3. Current ELN/NCCN CML guidelines. Https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1427
4. National Library of medicine. The development of dasatinib tablet as a treatment for chronic myeloid leukemia Https://pmc.ncbi.nlm.nih.gov/articles/PMC3825579/
5. ScienceDirect. Dasatinib.https://www.sciencedirect.com/topics/medicine-and-dentistry/dasatinib
Marketer Details
Bdr pharma
Author Details
Written By:
Nonish Sharma
I am a medical content writer with a strong academic background in life sciences, holding an M.Sc. in Biotechnology... Read More
Reviewed By:
Vaibhav Shakya
Dr. Vaibhav Shakya, MD, is a Medical reviewer and medicine expert at Globans Pharma, with more than 9 years of experienc... Read More
Want to know More
Check our Editor Policy
Disclaimer
Globanspharma main goal is to ensure that its consumers get correct, authentic, and reliable information that has been examined by medical professionals. This website's content has only been created for informational purposes. However, this is not meant to replace the medical advice and treatment given by a qualified physician. The information presented herein may not cover everything about particular lab tests, medicines, and health conditions, all possible side effects, and warnings. Please discuss all your queries related to any medication and illness with your doctor. We intend to support and maintain the doctor-patient relationship, not to substitute it or take its place.
